The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Congress 2022 | Changing clinical trial endpoints in MPNs & the link between hematopoietic fitness and outcomes
Joseph Scandura, MD, PhD, Weill Cornell Medicine and the New York Presbyterian Hospital, New York City, NY, emphasizes the need to change the endpoints that are currently used in clinical trials for myeloproliferative neoplasms (MPNs) to focus on survival measures, discussing the potential of hematopoietic fitness as a marker of event risk. This interview took place at the 14th International Congress on Myeloproliferative Neoplasms (MPN Congress) held in New York City, NY.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
